Pfenex (PFNX) Stock Price, News & Analysis

Company Overview

Pfenex Inc. was a biotechnology company focused on developing and commercializing complex protein therapeutics and biosimilars. Its proprietary Pfenex Expression Technology platform was designed to produce recombinant proteins efficiently and support the development of medicines for serious and chronic conditions.

The company’s best-known product was PF708, a recombinant form of teriparatide used to treat osteoporosis. The product was approved by the U.S. Food and Drug Administration under the brand name Bonsity and was commercialized through a partnership with Alvogen. Pfenex also maintained a pipeline of additional protein-based therapeutic candidates and pursued partnerships to advance and commercialize its products in international markets.

Founded in San Diego, California, Pfenex operated primarily in the United States while working with global pharmaceutical partners. In 2021, Ligand Pharmaceuticals acquired Pfenex, after which Pfenex ceased operating as an independent publicly traded company and its NYSE American listing was discontinued.

Key Stats

• Today's Range: $12.75 to $12.75
• 50-Day Range: $12.75 to $12.75
• 52-Week Range: $5.26 to $14.00
• Volume: N/A
• Average Volume: 503,865 shs
• Market Capitalization: $437.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 5/07/2020
• Today: 9/13/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSEAMERICAN:PFNX
• Previous Symbol: NYSEMKT:PFNX
• CIK: N/A
• Web: www.pfenex.com
• Phone: +1-858-3524400
• Fax: N/A
• Employees: 71
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 34,297,000
• Free Float: N/A
• Market Cap: $437.29 million
• Optionable: Not Optionable
• Beta: N/A